West Pharma (WST) Tops Q3 EPS by 27c; raises guidance

West Pharma (NYSE: WST) reported Q3 EPS of $1.96, $0.27 better than the analyst estimate of $1.69. Revenue for the quarter came in at $804.6 million versus the consensus estimate of $786.33 million.

GUIDANCE:

West Pharma sees Q4 2025 EPS of $1.81-$1.86, versus the consensus of $1.78. West Pharma sees Q4 2025 revenue of $790-800 million, versus the consensus of $796.4 million.

West Pharma sees FY2025 EPS of $7.06-$7.11, versus the consensus of $6.78. West Pharma sees FY2025 revenue of $3.06-3.07 billion, versus the consensus of $3.049 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Carnival Corp. (CCL) call put ratio 1.2 calls to 1 put into quarter results
• Western Digital (WDC) call put ratio 1 call to 1.2 puts a focus on January 17.50 puts into Korean market weakness and Micron (MU) quarter results